研究者業績
基本情報
- 所属
- 藤田医科大学 医学部 呼吸器外科学講座 准教授
- 学位
- 医学博士(東北大学)
- 研究者番号
- 00455833
- J-GLOBAL ID
- 201801021106693329
- researchmap会員ID
- B000314749
研究分野
4経歴
9-
2019年9月
-
2013年7月 - 2019年8月
-
2012年1月 - 2013年6月
-
2009年7月 - 2012年12月
-
2007年7月 - 2009年6月
学歴
2-
2001年4月 - 2005年3月
-
1992年4月 - 1998年3月
委員歴
1-
2019年4月 - 現在
受賞
5-
2017年1月
-
2010年8月
-
2010年7月
-
2009年6月
-
2005年5月
論文
109-
Transplantation proceedings 56(5) 1179-1182 2024年6月A 41-year-old woman with lymphangioleiomyomatosis developed a bronchial anastomotic stenosis after left single lung transplantation (LTx). A part of the hyperinflated right native lung was excised in an attempt to remedy the left lung compression, which appeared to affect the bronchial anastomotic stenosis and ventilation/perfusion mismatch. However, a persistent air leak after the surgery caused empyema and an open window thoracotomy (OWT) was performed. She remained oxygen-dependent and was relisted for lung transplantation. A right single LTx on the side of OWT was performed, achieving long-term survival with no activity limitations for the patient. We report here the first successful LTx after OWT for empyema.
-
Journal of thoracic disease 16(2) 1473-1479 2024年2月29日BACKGROUND: Despite the low number of lung transplantations (LTs) in Japan, 10 LT facilities are accredited and good outcomes have been reported. A database review was conducted to clarify the impact of case volume at LT facilities in Japan on short- and long-term outcomes. METHODS: All cadaveric LT cases treated between 2000 and 2021 in Japan were analyzed using the database of the Japanese Society of Lung and Heart-Lung Transplantation (JSLHT). The nine institutions represented were categorized into the low-volume (LV; <80 cumulative LT cases, <8 LTs/year, n=5) and high-volume (HV; ≥80 cumulative LT cases, ≥8 LTs/year, n=4) centers. Ninety-day and 1-year mortality, as well as 5- and 10-year survival data were evaluated. RESULTS: A total of 658 cadaveric LTs were performed at the nine institutions. The 90-day rates of mortality at the HV and LV centers were 3.5% and 3.9%, respectively (P=0.801), while the 1-year mortality rates were 9.2% and 11.5%, respectively (P=0.199). Additionally, log-rank analysis of Kaplan-Meier curves showing case volume did not reveal a significant difference in long-term survival between the HV and LV centers (P=0.272), though the LV centers had wide differences for long-term outcomes (P=0.030). CONCLUSIONS: Case volume did not have effects on short- or long-term outcomes following LT in Japan, while there were large variations in long-term outcomes among the LV centers compared to those of the HV centers.
-
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 63(6) 2023年6月1日OBJECTIVES: Standard bilateral lung transplantation (BLT) is not feasible for patients with pulmonary arterial hypertension (PAH) complicated with a giant pulmonary arterial aneurysm (PAA). This study aimed to describe the outcomes of BLT with pulmonary artery reconstruction (PAR) using donor aorta for such patients. METHODS: This is a retrospective single-centre study reviewing PAH patients with a PAA who received BLT with PAR using donor aorta from January 2010 through December 2020. We compared the characteristics and short- and long-term outcomes of recipients receiving PAR (PAR group) with those who had no PAA and received standard BLT (non-PAR group). RESULTS: Nineteen adult PAH patients underwent cadaveric lung transplantation during the study period. Among them, 5 patients with a giant PAA (median pulmonary artery trunk diameter, 69.9 mm) underwent BLT with PAR using donor aorta and the others received standard BLT. Although the operation time tended to be longer in the PAR group compared with the non-PAR group (1239 vs 958 mins, P = 0.087), 90-day mortality (PAR group: 0% vs non-PAR group: 14.3%, P > 0.99), and 5-year survival rate (PAR group: 100% vs non-PAR group: 85.7%, P = 0.74) was comparable between the groups. No dilatation, constriction or infection of the aortic grafts were recorded during the study period with a median follow-up time of 94 months in the PAR group. CONCLUSIONS: Lung transplantation with PAR using donor aorta is a valid surgical option for PAH patients complicated with a giant PAA.
-
Surgery today 2023年4月19日PURPOSE: To clarify the impact of donor and recipient characteristics on the survival of recipients before and after lung transplantation in the Japanese population. METHODS: Patients' data were collected for retrospective analysis from all authorized lung transplant centers in Japan. We included 1963 patients listed for lung transplantation by the end of December 2021, comprised of 658 deceased-donor and 270 living-donor lung transplants. RESULTS: Primary disease had a significant impact on the mortality of patients waiting for transplantation. The indications for transplant significantly affected the post-transplant survival rate of deceased-donor lung transplant recipients. The recipient's age also significantly affected the post-transplant survival rate of the deceased-donor and living-donor lung transplant recipients. The recipients of grafts transplanted from donors aged 61 years or older showed a worse post-transplant survival rate (≧60 years old). The survival rate for the combination of a female donor to a male recipient among the deceased-donor lung transplant recipients was the worst among the four combinations. CONCLUSION: The donor and recipient characteristics significantly impacted the survival of recipients after lung transplantation. The underlying mechanism of the negative impact of the gender mismatch of female donor to male recipient on post-transplant survival needs to be investigated further.
MISC
374-
移植 51(2-3) 81-83 2016年8月<p>Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease characterized by the proliferation of abnormal smooth muscle-like cells (LAM cells) that lead to cystic destruction of the lungs, chylous effusions, and the formation of lymphangioleiomyomas. Although lung transplantation for LAM accounts for only 1% of all lung transplant procedures in the International Registry, it does account for 16% in the Japanese Registry, and LAM is one of the major indications in Japanese lung transplantation. Recurrence of LAM in the allograft is one of the disease-specific complications after lung transplantation. The rates of recurrence, however, have been reported to be <10%, and the recurrence rarely affects the recipient's prognosis. Recently, sirolimus, an mTOR inhibitor, emerged as a therapeutic drug for LAM and is also expected to be effective for the recurrence of LAM after lung transplantation.</p>
-
移植 51(2-3) 244-244 2016年8月
-
JOURNAL OF HEART AND LUNG TRANSPLANTATION 35(4) S177-S178 2016年4月
-
JOURNAL OF HEART AND LUNG TRANSPLANTATION 35(4) S234-S234 2016年4月
-
内科 117(3) 471-474 2016年3月
-
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 193 2016年
-
Organ Biology 23(2) 141-144 2016年Mycophenolate mofetil (MMF) has been used as a standard immunosuppressive agent after lung transplantation. MMF is rapidly metabolized to active constituent, mycophenolic acid (MPA), after intake. Gastrointestinal side- effects and leukocytopenia are common adverse effects of MMF. Although, therapeutic drug monitoring (TDM) for calcineurin inhibitors is widely used, the role of TDM for MPA is unclear in lung transplantation. We investigated the correlation among the blood concentration of MPA, the dosage of MMF and the number of leukocyte in lung transplant recipients. The correlation coefficient between the blood concentration of MPA and the dosage of MMF was not significant, so MMF might require TDM. On the other hand, neither the correlation coefficients between the number of leukocyte and the blood concentration of MPA nor the correlation coefficients between the number of leukocyte and the dosage of MMF were not significant. Further investigation is necessary to find the meanings of TDM for MPA after lung transplantation.
-
移植 51(2) 81-83 2016年<p>Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease characterized by the proliferation of abnormal smooth muscle-like cells (LAM cells) that lead to cystic destruction of the lungs, chylous effusions, and the formation of lymphangioleiomyomas. Although lung transplantation for LAM accounts for only 1% of all lung transplant procedures in the International Registry, it does account for 16% in the Japanese Registry, and LAM is one of the major indications in Japanese lung transplantation. Recurrence of LAM in the allograft is one of the disease-specific complications after lung transplantation. The rates of recurrence, however, have been reported to be <10%, and the recurrence rarely affects the recipient's prognosis. Recently, sirolimus, an mTOR inhibitor, emerged as a therapeutic drug for LAM and is also expected to be effective for the recurrence of LAM after lung transplantation.</p>
-
胸部外科 69(1) 25-29 2016年1月高齢者肺切除例における術前の歯科への口腔ケア介入依頼状況と術後肺炎発症率について検討した。肺切除術を施行した65歳以上の159例(男性103名、女性56名、65〜84歳)を対象とした。術前の歯科医師による口腔ケア介入は61例で施行された。術後肺炎は4例で発症し、1例が死亡した。術前歯科医師への口腔ケア介入依頼率は、2013年30.3%、2014年45.8%と2014年で増加傾向を認めた。術後肺炎は2013年3例、2014年は1例で発症した。2013年の術後肺炎発症例3例中1例が在院死した。2014年には在院死はなかった。2013年の3例中2例はいずれも術前歯科非介入例であった。
-
TRANSPLANT INTERNATIONAL 28 306-306 2015年11月
-
TRANSPLANT INTERNATIONAL 28 521-521 2015年11月
-
TRANSPLANT INTERNATIONAL 28 376-376 2015年11月
-
日本医療薬学会年会講演要旨集 25 328-328 2015年10月23日
書籍等出版物
3担当経験のある科目(授業)
2-
2020年4月 - 現在気胸、転移性肺腫瘍、膿胸 (藤田医科大学)
-
縦隔腫瘍 (東北大学)
共同研究・競争的資金等の研究課題
13-
日本学術振興会 科学研究費助成事業 2020年10月 - 2024年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2019年4月 - 2024年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(B) 2019年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(B) 2018年4月 - 2022年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2018年4月 - 2021年3月